41
Participants
Start Date
July 31, 2007
Primary Completion Date
August 31, 2010
Study Completion Date
February 28, 2011
Ad6NSmut; AdCh3NSmut
2 doses Ad6NSmut 5 x 10\^8vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
Ad6NSmut; AdCh3NSmut
2 doses Ad6NSmut 5 x 10\^9vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
Ad6NSmut; AdCh3NSmut
2 doses Ad6NSmut 2.5 x 10\^10vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
AdCh3NSmut; Ad6NSmut
2 doses AdCh3NSmut 5 x 10\^8vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
AdCh3NSmut; Ad6NSmut
2 doses AdCh3NSmut 5 x 10\^9vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
AdCh3NSmut; Ad6NSmut
2 doses AdCh3NSmut 2.5 x 10\^10vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
Ad6NSmut; AdCh3NSmut
1 dose Ad6NSmut 2.5 x 10\^10vp at week 0 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 8.
AdCh3NSmut; Ad6NSmut
1 dose AdCh3NSmut 2.5 x 10\^10vp at week 0 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 8.
AdCh3NSmut; Ad6NSmut
1 dose AdCh3NSmut 7.5 x 10\^10vp at week 0 and 1 dose Ad6NSmut 7.5 x 10\^10vp at week 8.
Centre for Clinical Vaccinology and Tropical Medicine, Oxford
Wellcome Clinical Research Facility, Queen Elizabeth's Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham
University of Oxford
OTHER
ReiThera Srl
INDUSTRY